Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Diabetes mellitus4971 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A50682 | 35304191 | Mol Cell Endocrinol | Enterohepatic and non-canonical roles of farnesoid X receptor in controlling lipid and glucose metabolism. | 2022 | Details |
| A50690 | 35300452 | Indian J Endocrinol Metab | One-Hour Postload Plasma Glucose in Obese Indian Adults with Nonalcoholic Fatty Liver Disease: An Observational Study from North India. | 2022 | Details |
| A50718 | 35288342 | Clin Gastroenterol Hepatol | Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications. | 2022 | Details |
| A50724 | 35286799 | Clin Mol Hepatol | Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: a narrative review. | 2022 | Details |
| A50736 | 35283265 | Diabetes Res Clin Pract | Prevalence of non-alcoholic fatty liver disease (NAFLD) and its association with surrogate markers of insulin resistance in patients with type 1 diabetes. | 2022 | Details |
| A50745 | 35280867 | Front Med (Lausanne) | Efficacy of Off-Label Therapy for Non-alcoholic Fatty Liver Disease in Improving Non-invasive and Invasive Biomarkers: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. | 2022 | Details |
| A50749 | 35278680 | Ann Hepatol | Trends in drug prescriptions for type 2 diabetes, hypertension, and dyslipidemia among adults with non-alcoholic fatty liver disease. | 2022 | Details |
| A50755 | 35277004 | Nutrients | Fibroblast Growth Factor 19 and Fibroblast Growth Factor 21 Regulation in Obese Diabetics, and Non-Alcoholic Fatty Liver Disease after Gastric Bypass. | 2022 | Details |
| A50764 | 35276001 | J Clin Endocrinol Metab | Endotoxin Biomarkers Are Associated With Adiposity and Cardiometabolic Risk Across 6 Years of Follow-up in Youth. | 2022 | Details |
| A50769 | 35273160 | Nat Commun | Deep proteomic profiling unveils arylsulfatase A as a non-alcoholic steatohepatitis inducible hepatokine and regulator of glycemic control. | 2022 | Details |
| A50778 | 35269812 | Int J Mol Sci | Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A50783 | 35268466 | J Clin Med | The Coexistence of Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. | 2022 | Details |
| A50788 | 35266164 | Aliment Pharmacol Ther | Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know. | 2022 | Details |
| A50807 | 35234696 | Chin Med J (Engl) | Therapeutic developments in metabolic dysfunction-associated fatty liver disease. | 2022 | Details |
| A50809 | 35222274 | Front Endocrinol (Lausanne) | J-Shaped Relationship Between Serum Prolactin and Metabolic-Associated Fatty Liver Disease in Female Patients With Type 2 Diabetes. | 2022 | Details |
| A50810 | 35218717 | Eur J Pharmacol | HA-20 prevents hepatocyte steatosis in metabolic-associated fatty liver disease via regulating Ca2+ relative signalling pathways. | 2022 | Details |
| A50816 | 35195383 | Minerva Endocrinol (Torino) | Nonalcoholic liver disease in metabolic syndrome/type II diabetes mellitus patients: it is necessary to identify alcohol consumption. | 2022 | Details |
| A50830 | 35121749 | Sci Rep | A problem of proportions: estimates of metabolic associated fatty liver disease and liver fibrosis in Australian adults in the nationwide 2012 AusDiab Study. | 2022 | Details |
| A50831 | 35119217 | J Diabetes Investig | Assessing liver fibrosis in all patients with type 2 diabetes and fatty liver disease: It's time to act now. | 2022 | Details |
| A50838 | 35075677 | Hepatology | Letter to the editor: Circulating thrombospondin-2 as a biomarker in patients with NAFLD with and without diabetes-Are we convinced yet? | 2022 | Details |
| A50847 | 34992133 | Gut | Optimising the management of cardiovascular comorbidities in NAFLD patients: it's time to (re-) act! | 2022 | Details |
| A50875 | 34675888 | Front Endocrinol (Lausanne) | Cardiovascular Endocrinology: Evolving Concepts and Updated Epidemiology of Relevant Diseases. | 2021 | Details |
| A50879 | 34619075 | Cell Metab | A glimpse at the metabolic research in China. | 2021 | Details |
| A50892 | 34224877 | Clin Gastroenterol Hepatol | Liver Fibrosis in Asians With Metabolic Dysfunction-Associated Fatty Liver Disease. | 2021 | Details |
| A50897 | 34061630 | Diabetes Technol Ther | NAFLD and NASH and Diabetes. | 2021 | Details |
| A50900 | 35783905 | Hepatol Forum | The prevalence of metabolic-associated fatty liver disease in the Turkish population: A multicenter study. | 2021 | Details |
| A50903 | 33965575 | Clin Gastroenterol Hepatol | Prevalence of Fatty Liver Disease is Driven by Prediabetes and Diabetes: US NHANES 2017-2018. | 2021 | Details |
| A50958 | 30852101 | Arab J Gastroenterol | Managing diabetes and liver disease association: Practice guidelines from the Egyptian Association for the Study of Liver and Gastrointestinal Disease (EASLGD). | 2019 | Details |
| A50976 | 29279470 | Intern Med | Glycogen Hepatopathy: An Under-recognized Hepatic Complication of Uncontrolled Type 1 Diabetes Mellitus. | 2017 | Details |
| A50990 | 27822261 | Hepat Mon | The Cause-and-Effect Relationship Between Type 2 Diabetes Mellitus and Clinically Overt Cryptogenic Cirrhosis: A Matter That Must Be Seriously Revised. | 2016 | Details |
| A51008 | 26040518 | Aliment Pharmacol Ther | Editorial: diabetes and its association with hepatocellular carcinoma in chronic hepatitis B. | 2015 | Details |
| A51019 | 25043205 | Hepatology | Rationale for conducting a randomized trial to examine the efficacy of metformin in improving survival in cirrhosis: pleiotropic effects hypothesis. | 2014 | Details |
| A51034 | 23130768 | Aliment Pharmacol Ther | Commentary: Physical activity and NAFLD--cause or effect? | 2012 | Details |
| A51059 | 19015652 | Nat Clin Pract Gastroenterol Hepatol | What advice should be given to patients with NAFLD about the consumption of alcohol? | 2008 | Details |
| A51083 | 12619426 | Acta Gastroenterol Belg | NASH/NAFLD management. | 2003 | Details |
| A51089 | 35803839 | J Diabetes Complications | Elastographic parameters of liver steatosis and fibrosis predict independently the risk of incident chronic kidney disease and acute myocardial infarction in patients with type 2 diabetes mellitus. | 2022 | Details |
| A51091 | 35795859 | Oxid Med Cell Longev | Novel Insights into the Predictors of Obstructive Sleep Apnea Syndrome in Patients with Chronic Coronary Syndrome: Development of a Predicting Model. | 2022 | Details |
| A51105 | 35745205 | Nutrients | Metabolic Impact of MKP-2 Upregulation in Obesity Promotes Insulin Resistance and Fatty Liver Disease. | 2022 | Details |
| A51111 | 35702368 | Int J Gen Med | Gallstone Disease and Bacterial Metabolic Performance of Gut Microbiota in Middle-Aged and Older Patients. | 2022 | Details |
| A51119 | 35666055 | Hepatol Commun | Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C-Registry. | 2022 | Details |
| A51125 | 35617705 | J Med Food | Partial Replacement of High-Fat Diet with Beef Tallow Attenuates Dyslipidemia and Endoplasmic Reticulum Stress in db/db Mice. | 2022 | Details |
| A51128 | 35607596 | Drug Des Devel Ther | Effects of Ethanolic Extract of Schisandra sphenanthera on the Pharmacokinetics of Rosuvastatin in Rats. | 2022 | Details |
| A51129 | 35600376 | Front Oncol | The Importance of Metabolic Syndrome Status for the Risk of Non-Viral Hepatocellular Carcinoma: A Nationwide Population-Based Study. | 2022 | Details |
| A51138 | 35526895 | Chest | Middle Mediastinal Mass Compressing the Pulmonary Trunk in a Patient With a History of Breast Cancer. | 2022 | Details |
| A51142 | 35511325 | J Microbiol | Host-microbial interactions in metabolic diseases: from diet to immunity. | 2022 | Details |
| A51144 | 35502211 | Oxid Med Cell Longev | Research Progress of Ferroptosis in Adiposity-Based Chronic Disease (ABCD). | 2022 | Details |
| A51153 | 35458210 | Nutrients | The Dose-Response Effects of Consuming High Fructose Corn Syrup-Sweetened Beverages on Hepatic Lipid Content and Insulin Sensitivity in Young Adults. | 2022 | Details |
| A51188 | 35285920 | JAMA Netw Open | Association of Low- and No-Calorie Sweetened Beverages as a Replacement for Sugar-Sweetened Beverages With Body Weight and Cardiometabolic Risk: A Systematic Review and Meta-analysis. | 2022 | Details |
| A51227 | 10569299 | Am J Med | Association of nonalcoholic fatty liver disease with insulin resistance. | 1999 | Details |
| A51237 | 3829884 | Dig Dis Sci | Steatosis and cirrhosis in an obese diabetic. Resolution of fatty liver by fasting. | 1987 | Details |
| A51279 | 7187287 | Computertomographie | [Computer tomographic studies on the dynamics of liposynthesis and lipolysis of the human liver]. | 1981 | Details |
| A51308 | 35725292 | Gut | Hepatic events associated with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: a nationwide cohort study. | 2022 | Details |
| A51320 | 35629961 | Metabolites | Metabolomics in Bariatric and Metabolic Surgery Research and the Potential of Deep Learning in Bridging the Gap. | 2022 | Details |
| A51328 | 35588918 | Pharmacol Res | The effects of sodium-glucose cotransporter 2 inhibitors on hepatocellular carcinoma: From molecular mechanisms to potential clinical implications. | 2022 | Details |
| A51332 | 35535116 | J Clin Exp Hepatol | An Approach to the Management of Diabetes Mellitus in Cirrhosis: A Primer for the Hepatologist. | 2021 | Details |
| A51357 | 35332108 | Aging (Albany NY) | Mitophagy and mitochondrial dynamics in type 2 diabetes mellitus treatment. | 2022 | Details |
| A51396 | 35830001 | Drugs | Tirzepatide: First Approval. | 2022 | Details |
| A51420 | 35665672 | Transplant Rev (Orlando) | A comprehensive review of coronary artery disease in patients with end-stage liver disease. | 2022 | Details |
| A51426 | 35560370 | Hepatology | Lipocalin-2 Activates Hepatic stellate cells and Promotes Non-alcoholic Steatohepatitis in High-Fat Diet-Fed ob/ob mice. | 2022 | Details |
| A51432 | 35445894 | Surg Case Rep | Living donor liver transplantation for idiopathic portal hypertension with focal nodular hyperplasia. | 2022 | Details |
| A51433 | 35425398 | RSC Adv | Design, synthesis and evaluation of 3-phenoxypyrazine-2-carboxamide derivatives as potent TGR5 agonists. | 2022 | Details |
| A51449 | 35317186 | World J Hepatol | Glycogen hepatopathy in type-1 diabetes mellitus: A case report. | 2022 | Details |
| A51450 | 35315311 | Postgrad Med | What is clinically relevant weight loss for your patients and how can it be achieved? A narrative review. | 2022 | Details |
| A51497 | 35815420 | Hepatol Res | MAFLD Directly Related to Liver Fibrosis Independent of Insulin Resistance, Hyperlipidemia, and Alcohol Intake in Morbidly Obese Patients. | 2022 | Details |
| A51511 | 35710982 | Nat Rev Gastroenterol Hepatol | Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. | 2022 | Details |
| A51521 | 35655263 | Cardiovasc Diabetol | Impact of metabolic syndrome and metabolic dysfunction-associated fatty liver disease on cardiovascular risk by the presence or absence of type 2 diabetes and according to sex. | 2022 | Details |
| A51536 | 35491295 | Trends Endocrinol Metab | SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease. | 2022 | Details |
| A51553 | 35205361 | Genes (Basel) | Altered Mitochondrial Quality Control in Rats with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Induced by High-Fat Feeding. | 2022 | Details |
| A51555 | 35177915 | Diabetes Metab Syndr Obes | Associations Between GGT/HDL and MAFLD: A Cross-Sectional Study. | 2022 | Details |
| A51559 | 35140486 | Diabetes Metab Syndr Obes | Relationship Between Serum Uric Acid-to-Creatinine Ratio and the Risk of Metabolic-Associated Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus. | 2022 | Details |
| A51564 | 35082506 | Diabetes Metab Syndr Obes | Metabolic Dysfunction-Associated Fatty Liver Disease Increases the Risk of Gastroesophageal Reflux Symptoms. | 2022 | Details |
| A51565 | 35081898 | Endocr Metab Immune Disord Drug Targets | Therapeutic effects and mechanism of liraglutide on rats with type 2 diabetes and metabolic-associated fatty liver disease. | 2022 | Details |
| A51573 | 34985050 | Eur J Gastroenterol Hepatol | Metabolic associated fatty liver disease and acute-on-chronic liver failure: common themes for common problems. | 2021 | Details |
| A51574 | 34975521 | Front Physiol | Monocyte to High-Density Lipoprotein Cholesterol Ratio at the Nexus of Type 2 Diabetes Mellitus Patients With Metabolic-Associated Fatty Liver Disease. | 2021 | Details |
| A51575 | 34965034 | Acta Gastroenterol Belg | The prevalence of disorders of the gut-brain axis in type 2 diabetes mellitus patients with metabolic dysfunction-associated fatty liver disease: an observational study. | 2021 | Details |
| A51580 | 34889064 | J Diabetes Investig | Circulating level of fatty acid-binding protein 4 is an independent predictor of metabolic dysfunction-associated fatty liver disease in middle-aged and elderly individuals. | 2022 | Details |
| A51583 | 34869329 | Front Cell Dev Biol | Combined Analysis of Expression Profiles in a Mouse Model and Patients Identified BHMT2 as a New Regulator of Lipid Metabolism in Metabolic-Associated Fatty Liver Disease. | 2021 | Details |
| A51589 | 34751487 | Hepatol Res | Metabolic dysfunction-associated fatty liver disease and liver fibrosis: Prevalence and associated factors in the middle-aged and older US population. | 2021 | Details |
| A51613 | 35660447 | Sci Total Environ | Metabolomics-based safety evaluation of acute exposure to electronic cigarettes in mice. | 2022 | Details |
| A51616 | 35620719 | Front Med (Lausanne) | Predictive and Prognostic Roles of Gut Microbial Variation in Liver Transplant. | 2022 | Details |
| A51619 | 35574038 | Front Endocrinol (Lausanne) | Role of Innate lymphoid Cells in Obesity and Insulin Resistance. | 2022 | Details |
| A51621 | 35550438 | Drug Discov Today | Key regulatory miRNAs in lipid homeostasis: Implications for cardiometabolic diseases and development of novel therapeutics. | 2022 | Details |
| A51629 | 35487614 | Clin Liver Dis | Chronic Kidney Disease After Liver Transplantation. | 2022 | Details |
| A51638 | 35421452 | Life Sci | Characteristics and molecular mechanisms through which SGLT2 inhibitors improve metabolic diseases: A mechanism review. | 2022 | Details |
| A51644 | 35305637 | BMC Endocr Disord | Prevalence of prediabetes and associated factors in southwest iran: results from Hoveyzeh cohort study. | 2022 | Details |
| A51647 | 35291709 | Spartan Med Res J | Is Fat Deposition of Renal Sinus a Concomitant Finding to Fatty Liver Disease? The First Study Regarding the Relationship Between Kidney and Liver Fat Content with Non-Contrast Computed Tomography. | 2022 | Details |
| A51651 | 35268696 | Molecules | A Comprehensive Review on Therapeutic Perspectives of Phytosterols in Insulin Resistance: A Mechanistic Approach. | 2022 | Details |
| A51654 | 35224857 | Liver Transpl | Results of a multidisciplinary strategy to improve the management of cardiovascular risk factors after liver transplantation. | 2022 | Details |
| A51664 | 35115945 | Front Pharmacol | Anti-Inflammatory and Pro-Autophagy Effects of the Cannabinoid Receptor CB2R: Possibility of Modulation in Type 1 Diabetes. | 2022 | Details |
| A51669 | 35070060 | World J Diabetes | Gut microbiota-derived metabolites are novel targets for improving insulin resistance. | 2022 | Details |
| A51674 | 35040267 | Physiol Rep | Macrophage activation marker sCD163 is associated with liver injury and hepatic insulin resistance in obese patients before and after Roux-en-Y gastric bypass. | 2022 | Details |
| A51681 | 34959746 | Nutrients | Blueberry Counteracts Prediabetes in a Hypercaloric Diet-Induced Rat Model and Rescues Hepatic Mitochondrial Bioenergetics. | 2021 | Details |
| A51682 | 34958818 | Metabolism | The clustering of Cardiovascular, Renal, Adipo-Metabolic Eye and Liver disease with type 2 diabetes. | 2021 | Details |
| A51686 | 34920733 | Cardiovasc Diabetol | Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride. | 2021 | Details |
| A51690 | 34904501 | Expert Rev Endocrinol Metab | Understanding the pathophysiologic pathways that underlie obesity and options for treatment. | 2021 | Details |
| A51705 | 34774157 | Lancet Gastroenterol Hepatol | Metabolic dysfunction-associated fatty liver disease and insulin resistance in type 1 diabetes. | 2021 | Details |
| A51706 | 34758301 | Cell Rep | The hepatic compensatory response to elevated systemic sulfide promotes diabetes. | 2021 | Details |
| A51717 | 34647708 | Ann Surg | Duodenal-Jejunal Bypass Liner for the management of Type 2 Diabetes Mellitus and Obesity: A Multicenter Randomized Controlled Trial. | 2022 | Details |
| A51719 | 34629258 | Nutr Metab Cardiovasc Dis | Changes in markers of hepatic steatosis and fibrosis in patients with type 2 diabetes during treatment with glucagon-like peptide-1 receptor agonists. A multicenter retrospective longitudinal study. | 2021 | Details |
| A51721 | 34603196 | Front Endocrinol (Lausanne) | Serum Afamin a Novel Marker of Increased Hepatic Lipid Content. | 2021 | Details |